Sunday , November 29 2020
Home / Michel Accad, Anish Koka /Andrew Althouse on Clinical Trial Design and Remdesivir

Andrew Althouse on Clinical Trial Design and Remdesivir

Summary:
Our guest is Andrew Althouse, statistician at the Center for Clinical Trials and Data coordination in Pittsburgh. He holds an undergraduate degree in Statistics and a PhD in Epidemiology from the University of Pittsburgh. His main area of interest is the design of randomized control trials. He discusses adaptive randomized control trials, and dissects the ...

Topics:
Michel Accad, Anish Koka considers the following as important:

This could be interesting, too:

Tyler Durden writes 2021 Would Be A Great Time To Audit The Fed

Tyler Durden writes Cali Mansion Once Listed For 0 Million Sells For “Only” .4 Million

Tyler Durden writes The Strangely Unscientific Masking Of America

Tyler Durden writes The 2021 Liquidity Supernova: Step Aside Fed – US Treasury Will Unleash .3 Trillion In Liquidity

Our guest is Andrew Althouse, statistician at the Center for Clinical Trials and Data coordination in Pittsburgh. He holds an undergraduate degree in Statistics and a PhD in Epidemiology from the University of Pittsburgh. His main area of interest is the design of randomized control trials. He discusses adaptive randomized control trials, and dissects the recent news of the positive Remdesivir trial.

Leave a Reply

Your email address will not be published. Required fields are marked *